OBJECTIVES: The objective was to test the hypothesis that oxycodone/acetaminophen provides superior analgesia to hydrocodone/acetaminophen for the treatment of acute extremity pain following emergency department (ED) discharge. METHODS: This was a prospective, randomized, double-blind clinical trial of nonelderly adult ED patients with acute musculoskeletal extremity pain, randomly allocated at discharge to receive oxycodone/acetaminophen (5 mg/325 mg) or hydrocodone/acetaminophen (5 mg/325 mg). The primary outcome was the between-group difference in improvement in numerical rating scale (NRS) pain scores over a 2-hour period following the most recent ingestion of study drug, obtained during telephone contact 24 hours after ED discharge. Secondary outcomes included proportionate decrease in pain, comparative side-effect profiles, and patient satisfaction. RESULTS: A total of 240 patients were enrolled. The final sample consisted of 220 patients, 107 randomly allocated tooxycodone/acetaminophen and 113 to hydrocodone/acetaminophen. At 24 hours after ED discharge, the mean NRS pain scores prior to the most recent dose of outpatient pain medication were 7.8 and 7.9 in the oxycodone/acetaminophen and hydrocodone/acetaminophen groups, respectively. The mean decreases in pain scores over 2 hours were 4.4 NRS units in the oxycodone/acetaminophen group versus 4.0 NRS units in the hydrocodone/acetaminophen group, for a difference of 0.4 NRS units (95% confidence interval = -0.2 to 1.1 NRS units). Satisfaction with the analgesics was similar. CONCLUSIONS: This study design could not detect a clinically or statistically significant difference in analgesic efficacy between oxycodone/acetaminophen (5 mg/325 mg) and hydrocodone/acetaminophen (5 mg/325 mg) for treatment of acute musculoskeletal extremity pain in adults following ED discharge. Both opioids reduced pain scores by approximately 50%.
RCT Entities:
OBJECTIVES: The objective was to test the hypothesis that oxycodone/acetaminophen provides superior analgesia to hydrocodone/acetaminophen for the treatment of acute extremity pain following emergency department (ED) discharge. METHODS: This was a prospective, randomized, double-blind clinical trial of nonelderly adult ED patients with acute musculoskeletal extremity pain, randomly allocated at discharge to receive oxycodone/acetaminophen (5 mg/325 mg) or hydrocodone/acetaminophen (5 mg/325 mg). The primary outcome was the between-group difference in improvement in numerical rating scale (NRS) pain scores over a 2-hour period following the most recent ingestion of study drug, obtained during telephone contact 24 hours after ED discharge. Secondary outcomes included proportionate decrease in pain, comparative side-effect profiles, and patient satisfaction. RESULTS: A total of 240 patients were enrolled. The final sample consisted of 220 patients, 107 randomly allocated to oxycodone/acetaminophen and 113 to hydrocodone/acetaminophen. At 24 hours after ED discharge, the mean NRS pain scores prior to the most recent dose of outpatientpain medication were 7.8 and 7.9 in the oxycodone/acetaminophen and hydrocodone/acetaminophen groups, respectively. The mean decreases in pain scores over 2 hours were 4.4 NRS units in the oxycodone/acetaminophen group versus 4.0 NRS units in the hydrocodone/acetaminophen group, for a difference of 0.4 NRS units (95% confidence interval = -0.2 to 1.1 NRS units). Satisfaction with the analgesics was similar. CONCLUSIONS: This study design could not detect a clinically or statistically significant difference in analgesic efficacy between oxycodone/acetaminophen (5 mg/325 mg) and hydrocodone/acetaminophen (5 mg/325 mg) for treatment of acute musculoskeletal extremity pain in adults following ED discharge. Both opioids reduced pain scores by approximately 50%.
Authors: Patrick Richard; Mark R Bauer; Natalie Moresco; Regine Walker; Diana Bowser; Demarcio Reed; Mary Jo Larson Journal: J Am Dent Assoc Date: 2020-12-24 Impact factor: 3.634
Authors: Scott G Weiner; Michelle A Hendricks; Sanae El Ibrahimi; Grant A Ritter; Sara E Hallvik; Christi Hildebran; Roger D Weiss; Edward W Boyer; Diana P Flores; Lewis S Nelson; Peter W Kreiner; Michael A Fischer Journal: PLoS One Date: 2022-04-05 Impact factor: 3.240
Authors: Kevin J Duffy; Katharyn L Flickinger; Jeffrey T Kristan; Melissa J Repine; Alexandro Gianforcaro; Rebecca B Hasley; Saad Feroz; Jessica M Rupp; Jumana Al-Baghli; Maria L Pacella; Brian P Suffoletto; Clifton W Callaway Journal: J Pain Res Date: 2017-05-24 Impact factor: 3.133
Authors: Clément Le Cornec; Said Lariby; Vivien Brenckmann; Jean Benoit Hardouin; Claude Ecoffey; Marion Le Pottier; Philippe Fradin; Hélène Broch; Amine Kabbaj; Yannick Auffret; Florence Deciron; Céline Longo; François Javaudin; Quentin Le Bastard; Joël Jenvrin; Emmanuel Montassier Journal: Trials Date: 2018-05-02 Impact factor: 2.279